Hypermobility
Hypermobility is the ability to move a joint beyond the normal range of motion. It can be limited to individual joints or occur more generally throughout the body. In most cases hypermobility is benign, but unstable joints are prone to injuries, dislocations, and subluxations which can cause significant pain.
Last Updated:October 13, 2024
Hypermobility is the ability to move one or more joints beyond the normal range of motion. In most cases, hypermobility is benign, but it can be accompanied by pain, soft-tissue trauma, and other features of Hypermobility Spectrum Disorder (HSD). Hypermobility is also present in some connective tissue disorders, such as Ehlers-Danlos Syndrome (EDS).
Excessive joint range of motion is the primary sign of hypermobility, but common reasons for seeking medical support include pain, injury, and joint instability. Although the cause is unclear, hypermobility is also associated with increased prevalence of anxiety, fatigue, immune dysfunction, autonomic nervous system dysfunction, sleep disturbances, gastrointestinal problems, and gynecological complications.[1]
The Beighton Hypermobility Score is used to quantify hypermobility and includes a nine-point scoring system. Conditions such as EDS and HSD have specific criteria with additional features.
There are no supplements which reduce hypermobility directly. However, some supplements may support goals related to the condition, such as protein for fueling resistance-training adaptations, or melatonin for improving sleep to support healing.
Although deficiencies in some nutrients (e.g., vitamin C) can result in compromised connective tissue, there is no single best diet for hypermobile individuals. More often, diets are tailored on an individual level to navigate conditions or sensitivities which may occur alongside hypermobility, such as gastrointestinal dysfunction.
Low impact exercise options such as swimming are popular, and research suggests that appropriately tailored resistance training may improve joint control, strengthen muscles and tendons, and reduce pain in hypermobile joints.[4] Symptom management varies between individuals, but may involve braces for affected joints, avoidance of high-impact jobs and hobbies, or scheduling around fatigue.[5]
- ^Hakim A, Grahame RJoint hypermobility.Best Pract Res Clin Rheumatol.(2003-Dec)
- ^Engelbert RH, Juul-Kristensen B, Pacey V, de Wandele I, Smeenk S, Woinarosky N, Sabo S, Scheper MC, Russek L, Simmonds JVThe evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome.Am J Med Genet C Semin Med Genet.(2017-03)
- ^Nagori SA, Jose A, Gopalakrishnan V, Roy ID, Chattopadhyay PK, Roychoudhury AThe efficacy of dextrose prolotherapy over placebo for temporomandibular joint hypermobility: A systematic review and meta-analysis.J Oral Rehabil.(2018-Dec)
- ^Liaghat B, Skou ST, Jørgensen U, Sondergaard J, Søgaard K, Juul-Kristensen BHeavy shoulder strengthening exercise in people with hypermobility spectrum disorder (HSD) and long-lasting shoulder symptoms: a feasibility study.Pilot Feasibility Stud.(2020)
- ^Russek LN, Stott P, Simmonds JRecognizing and Effectively Managing Hypermobility-Related Conditions.Phys Ther.(2019-09-01)
- ^Remvig L, Jensen DV, Ward RCEpidemiology of general joint hypermobility and basis for the proposed criteria for benign joint hypermobility syndrome: review of the literature.J Rheumatol.(2007-Apr)
- ^Rek M, Kaczmarek K, Cygankiewicz I, Wranicz JK, Ptaszyński PPostural orthostatic tachycardia syndrome (POTS)--pathophysiology, diagnostics, and treatment.Przegl Lek.(2014)
- ^Borba VV, Zandman-Goddard G, Shoenfeld YProlactin and Autoimmunity.Front Immunol.(2018)
- ^Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, Bloom L, Bowen JM, Brady AF, Burrows NP, Castori M, Cohen H, Colombi M, Demirdas S, De Backer J, De Paepe A, Fournel-Gigleux S, Frank M, Ghali N, Giunta C, Grahame R, Hakim A, Jeunemaitre X, Johnson D, Juul-Kristensen B, Kapferer-Seebacher I, Kazkaz H, Kosho T, Lavallee ME, Levy H, Mendoza-Londono R, Pepin M, Pope FM, Reinstein E, Robert L, Rohrbach M, Sanders L, Sobey GJ, Van Damme T, Vandersteen A, van Mourik C, Voermans N, Wheeldon N, Zschocke J, Tinkle BThe 2017 international classification of the Ehlers-Danlos syndromes.Am J Med Genet C Semin Med Genet.(2017-03)
- ^What is HSD?
- ^Gensemer C, Burks R, Kautz S, Judge DP, Lavallee M, Norris RAHypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.Dev Dyn.(2021-03)